| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-47797-0.1mg | |||
| IHC-Prediluted | NBP2-48309 | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 350 | IC7106U-100UG | |||
| Alexa Fluor 405 | IC7106V-100UG | |||
| Alexa Fluor 488 | IC7106G | |||
| Alexa Fluor 594 | IC7106T-100UG | |||
| Alexa Fluor 647 | IC7106R-100UG | |||
| Alexa Fluor 700 | IC7106N-100UG | |||
| Alexa Fluor 750 | IC7106S-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB7106-SP | |||
| Carrier Free | IC7106G | |||
| Carrier Free | IC7106V-100UG | |||
| Carrier Free | IC7106U-100UG | |||
| Carrier Free | IC7106T-100UG | |||
| Carrier Free | IC7106S-100UG | |||
| Carrier Free | IC7106R-100UG | |||
| Carrier Free | IC7106N-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-33066 | |||
| IHC-Prediluted | NBP2-44365 | |||
![Western Blot: ER beta/NR3A2 Antibody (14C8) [NB200-305] - Non-transfected (-) and transfected (+) 293T whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with diluted at 1:5000.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-(14C8)-Western-Blot-NB200-305-img0006.jpg "Western Blot: ER beta/NR3A2 Antibody (14C8) [NB200-305] - Non-transfected (-) and transfected (+) 293T whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with diluted at 1:5000.")
![Immunohistochemistry-Paraffin: Estrogen Receptor beta Antibody (14C8) [NB200-305] - Infiltrating lobular carcinoma of the breast.](http://images.novusbio.com/fullsize2/Estrogen Receptor beta Antibody (14C8)-Immunohistochemistry-Paraffin-NB200-305-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: ER beta/NR3A2 Antibody [NB120-3577] - Primate amygdala.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-Immunocytochemistry-Immunofluorescence-NB120-3577-img0003.jpg "Immunocytochemistry/Immunofluorescence: ER beta/NR3A2 Antibody [NB120-3577] - Primate amygdala.")
![Immunohistochemistry-Paraffin: ER beta/NR3A2 Antibody [NB120-3577] - Figure 1 illustrates immunolocalization of ER beta in primate amygdala using NB120-3577.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-Immunohistochemistry-Paraffin-NB120-3577-img0004.jpg)
![Western Blot: ER beta/NR3A2 Antibody ([PPG5/10]) - Azide and BSA Free [NBP2-61944] - Clone PPG5/10 used to detect expression of ER beta/NR3A2 in colorectal tissue by Western Blot. (A) ER beta/NR3A2, 2 and 5 mRNA expression (assessed by RT-PCR) and (B) ER beta/NR3A2 and ER beta 2 protein expression (assessed by western blotting) by 10 colorectal carcinoma cell lines.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([PPG5-10])---Azide-and-BSA-Free-Western-Blot-NBP2-61944-img0009.jpg "Western Blot: ER beta/NR3A2 Antibody ([PPG5/10]) - Azide and BSA Free [NBP2-61944] - Clone PPG5/10 used to detect expression of ER beta/NR3A2 in colorectal tissue by Western Blot. (A) ER beta/NR3A2, 2 and 5 mRNA expression (assessed by RT-PCR) and (B) ER beta/NR3A2 and ER beta 2 protein expression (assessed by western blotting) by 10 colorectal carcinoma cell lines.")
![Immunocytochemistry/Immunofluorescence: ER beta/NR3A2 Antibody ([PPG5/10]) - Azide and BSA Free [NBP2-61944] - Clone PPG5/10 used to detect expression of ER beta/NR3A2 in cancer tissue by Immunofluorescence. Expression of PR paralleled that of ER alpha, not ER beta. Fluorescent co-localization as carried out using antibodies specific for ER alpha or ER beta/NR3A2 (both green) and PR (red). The cancers illustrated were classified as well (code 1614), moderately (code 1930) or poorly (c, codes 0001 and 1176) differentiated; at least 8 samples were analyzed in each group. Co-expression was detected as yellow/orange immunofluorescence. In the well and moderately-differentiated cancers, expression of PR was most intense in epithelial cells and broadly overlapped with that of ER alpha (e.g. in cells indicated by arrows).](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([PPG5-10])---Azide-and-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP2-61944-img0004.jpg)
![Immunohistochemistry: ER beta/NR3A2 Antibody ([PPG5/10]) - Azide and BSA Free [NBP2-61944] - Clone PPG5/10 used to detect expression of ER beta/NR3A2 in cancer tissue by Western Blot. Examples of ER beta/NR3A2 (a, d, e), ER beta 2 (b, f, g), ER beta/NR3A2 (c, h) and TFF1 (i) immunohistochemistry performed on normal colorectal epithelium (a-c) and colorectal carcinoma (d-i).](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([PPG5-10])---Azide-and-BSA-Free-Immunohistochemistry-NBP2-61944-img0007.jpg)
![Western Blot: ER beta/NR3A2 Antibody ([PPG5/10]) - Azide and BSA Free [NBP2-61944] - Clone PPG5/10 used to detect expression of ER beta/NR3A2 in cancer tissue by Western Blot. (B) Western blot of ER beta detection in villous trophoblast cell lysate. Lane 1: normal placenta; Lane 2: preeclamptic placenta; Lane 3: IUGR placenta.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([PPG5-10])---Azide-and-BSA-Free-Western-Blot-NBP2-61944-img0008.jpg)
![Immunohistochemistry: ER beta/NR3A2 Antibody ([PPG5/10]) - Azide and BSA Free [NBP2-61944] - Clone PPG5/10 used to detect expression of ER beta/NR3A2 in endometrial cancer tissue by IHC-P. Tissues were classified as well (A-D), moderately (E-H) or poorly (J-M) differentiated; main panels show closely adjacent sections from three cancer blocks to allow direct comparisons.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([PPG5-10])---Azide-and-BSA-Free-Immunohistochemistry-NBP2-61944-img0002.jpg)
![Immunohistochemistry: ER beta/NR3A2 Antibody ([PPG5/10]) - Azide and BSA Free [NBP2-61944] - Clone PPG5/10 used to detect expression of ER beta/NR3A2 in cancer tissue by IHC-P. Prostate carcinoma Gleason score 3+3 showing > 70% positive nuclei stained by IHC.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([PPG5-10])---Azide-and-BSA-Free-Immunohistochemistry-NBP2-61944-img0003.jpg)
![Immunohistochemistry: ER beta/NR3A2 Antibody ([PPG5/10]) - Azide and BSA Free [NBP2-61944] - Clone PPG5/10 used to detect expression of ER beta/NR3A2 in cancer tissue by IHC-P.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([PPG5-10])---Azide-and-BSA-Free-Immunohistochemistry-NBP2-61944-img0005.jpg)
![Immunohistochemistry: ER beta/NR3A2 Antibody ([PPG5/10]) - Azide and BSA Free [NBP2-61944] - Clone PPG5/10 used to detect expression of ER beta/NR3A2 in cancer tissue by IHC-P. Expression of estrogen receptor (ER) beta (indicated by arrows) in normal syncytiotrophoblasts preeclamptic (A), syncytiotrophoblast (B), and intrauterine growth restriction (C). Expression of ER beta/NR3A2 was also detected in extravillous trophoblast cells of normal-term placentas (D), preeclamptic placentas (E), and intrauterine growth-restricted placentas (F); 25x lens.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([PPG5-10])---Azide-and-BSA-Free-Immunohistochemistry-NBP2-61944-img0006.jpg)
![Immunohistochemistry-Paraffin: ER beta/NR3A2 Antibody (ESR2/686) [NBP2-44366] - Human Ovarian Carcinoma stained with ER-beta1 Monoclonal Antibody (ESR2/686).](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-(ESR2-686)-Immunohistochemistry-Paraffin-NBP2-44366-img0006.jpg "Immunohistochemistry-Paraffin: ER beta/NR3A2 Antibody (ESR2/686) [NBP2-44366] - Human Ovarian Carcinoma stained with ER-beta1 Monoclonal Antibody (ESR2/686).")
![Flow Cytometry: ER beta/NR3A2 Antibody (ESR2/686) [NBP2-44366] - Flow Cytometry: ER beta/NR3A2 Antibody (ESR2/686) [Phycoerythrin] [NBP2-47797PE] - An intracellular stain was performed on MCF-7 cells with ER Beta/NR3A2 (ESR2/686) NBP2-47797PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin. Image using the PE form of this antibody.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-(ESR2-686)-Flow-Cytometry-NBP2-44366-img0008.jpg)
![Immunohistochemistry-Paraffin: ER beta/NR3A2 Antibody (ESR2/686) [NBP2-44366] - Human Bladder Carcinoma stained with ER-beta1 Monoclonal Antibody (ESR2/686).](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-(ESR2-686)-Immunohistochemistry-Paraffin-NBP2-44366-img0003.jpg)
![Immunohistochemistry-Paraffin: ER beta/NR3A2 Antibody (ESR2/686) [NBP2-44366] - Human Breast Carcinoma stained with ER-beta1 Monoclonal Antibody (ESR2/686).](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-(ESR2-686)-Immunohistochemistry-Paraffin-NBP2-44366-img0004.jpg)
![Immunohistochemistry-Paraffin: ER beta/NR3A2 Antibody (ESR2/686) [NBP2-44366] - Human Gastric Carcinoma stained with ER-beta1 Monoclonal Antibody (ESR2/686).](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-(ESR2-686)-Immunohistochemistry-Paraffin-NBP2-44366-img0005.jpg)
![Flow Cytometry: ER beta/NR3A2 Antibody (ESR2/686) [NBP2-44366] - Human ER-beta on MCF-7 Cells. Black: Cells alone; Green: Isotype Control; Red: PE-labeled ER-beta1 Monoclonal Antibody (ESR2/686).](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-(ESR2-686)-Flow-Cytometry-NBP2-44366-img0001.jpg)
![Flow Cytometry: ER beta/NR3A2 Antibody (ESR2/686) [NBP2-44366] - Human ER beta on BT474 Cells. Black: Cells alone; Grey: Isotype Control; Green: AF488-labeled ER beta1 Monoclonal Antibody (ESR2/686).](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-(ESR2-686)-Flow-Cytometry-NBP2-44366-img0002.jpg)
![SDS-Page: ER beta/NR3A2 Antibody (ESR2/686) [NBP2-44366]](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-(ESR2-686)-SDS-Page-NBP2-44366-img0007.jpg)
![Western Blot: ER beta/NR3A2 Antibody ([57/3]) - Azide and BSA Free [NBP2-61943] - Clone 57/3 used to detect expression of ER beta/NR3A2 in Leydig cell tumors by Western Blot. Immunoblots of aromatase and estrogen receptors from protein extracts of Leydig cell tumors and control tissues. Aromatase: rat ovary (C+), negative control (C-), Leydig cell tumors (lanes 1 and 2). ER alpha: rat ovary (C+), negative control (C-), Leydig cell tumors (lanes 1 and 2). ER beta 1: control human testis (C+), negative control (C-), Leydig cell tumors (lanes 1 and 2). ER beta/NR3A2: control human testis (C+), negative control (C-), Leydig cell tumors (lanes 1 and 2). beta-Actin serves as a loading control.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([57-3])---Azide-and-BSA-Free-Western-Blot-NBP2-61943-img0011.jpg "Western Blot: ER beta/NR3A2 Antibody ([57/3]) - Azide and BSA Free [NBP2-61943] - Clone 57/3 used to detect expression of ER beta/NR3A2 in Leydig cell tumors by Western Blot. Immunoblots of aromatase and estrogen receptors from protein extracts of Leydig cell tumors and control tissues. Aromatase: rat ovary (C+), negative control (C-), Leydig cell tumors (lanes 1 and 2). ER alpha: rat ovary (C+), negative control (C-), Leydig cell tumors (lanes 1 and 2). ER beta 1: control human testis (C+), negative control (C-), Leydig cell tumors (lanes 1 and 2). ER beta/NR3A2: control human testis (C+), negative control (C-), Leydig cell tumors (lanes 1 and 2). beta-Actin serves as a loading control.")
![Immunocytochemistry/Immunofluorescence: ER beta/NR3A2 Antibody ([57/3]) - Azide and BSA Free [NBP2-61943] - Clone 57/3 used to detect expression of ER beta/NR3A2 in ovarian cancer cells by Immunofluorescence. A) Representative pictures for ER alpha, ER beta 1, ER beta 2, ER beta/NR3A2, PR, and AR immunostaining in LGSOC patients (magnification 20x) and bar chart showing levels of hormone receptor expression (mean +/- SEM, n = 25). Results are expressed as IRS (Immunoreactive receptor score). B) Representative pictures showing exclusive nuclear and nuclear/cytoplasmic ER beta/NR3A2 expression in primary tumor and matched peritoneal metastasis.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([57-3])---Azide-and-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP2-61943-img0002.jpg)
![Immunohistochemistry: ER beta/NR3A2 Antibody ([57/3]) - Azide and BSA Free [NBP2-61943] - Clone 57/3 used to detect expression of ER beta/NR3A2 in Leydig cell tumors by IHC-P. Morphology and immunolocalization of aromatase and estrogen receptors in Leydig cell tumors (A and B) and control testis (C). A-C: Hematoxylin-eosin staining. A1-C1: Aromatase immunolocalization. A2-C2: ER alpha immunoreactivity. A3-C3: ER beta 1 immunodetection. A4-C4: ER beta/NR3A2 immunolocalization. L, Leydig cells; T, seminiferous tubule.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([57-3])---Azide-and-BSA-Free-Immunohistochemistry-NBP2-61943-img0009.jpg)
![Western Blot: ER beta/NR3A2 Antibody ([57/3]) - Azide and BSA Free [NBP2-61943] - Clone 57/3 used to detect expression of ER beta/NR3A2 in colorectal tissue by Western Blot. (A) ER beta1, ER beta/NR3A2 and ER beta 5 mRNA expression (assessed by RT-PCR) and (B) ER beta 1 and ER beta/NR3A2 protein expression (assessed by western blotting) by 10 colorectal carcinoma cell lines.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([57-3])---Azide-and-BSA-Free-Western-Blot-NBP2-61943-img0010.jpg)
![Immunohistochemistry: ER beta/NR3A2 Antibody ([57/3]) - Azide and BSA Free [NBP2-61943] - Clone 57/3 used to detect expression of ER beta/NR3A2 in cancer tissue by IHC-P. Tissues were classified as well (A-D), moderately (E-H) or poorly (J-M) differentiated; immunoexpression of ER beta 1, ER beta/NR3A2, ER beta 5 was readily detected (K. L, M). Inserts in panels K, L, and M show negative controls using primary antibodies pre-absorbed with specific peptides used for immunization. Asterisks (*) label the stromal compartment that was well defined in the well differentiated cancers.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([57-3])---Azide-and-BSA-Free-Immunohistochemistry-NBP2-61943-img0003.jpg)
![Immunohistochemistry: ER beta/NR3A2 Antibody ([57/3]) - Azide and BSA Free [NBP2-61943] - Clone 57/3 used to detect expression of ER beta/NR3A2 in cancer tissue by IHC-P. A) Immunostaining for ER beta 1 was significantly higher in tumors from females compared to males (p<0.01); B) and C) Tumor levels of ER beta/NR3A2 and ER beta 5 did not significantly differ between females and males. All results are expressed as the mean -/+ SEM (n=6 tumors/group). Representative stained section of tumors from females and males are shown (magnification 40x).](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([57-3])---Azide-and-BSA-Free-Immunohistochemistry-NBP2-61943-img0005.jpg)
![Immunohistochemistry: ER beta/NR3A2 Antibody ([57/3]) - Azide and BSA Free [NBP2-61943] - Clone 57/3 used to detect ER beta/NR3A2 expression in normal human liver by IHC-P. Staining pattern of the ER beta isoforms in human liver. In order to confirm the specificity of the ER beta antibodies used in the study, sections of healthy human liver were immunostained, showing that ER beta 1 and ER beta/NR3A2 isoforms are not expressed, while specific nuclear ER beta 5 immunoreactivity is detected (magnification 20x and 40x). This pattern of ER beta isoforms' immunoreactivity is consistent with previous descriptions.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([57-3])---Azide-and-BSA-Free-Immunohistochemistry-NBP2-61943-img0007.jpg)
![Immunohistochemistry: ER beta/NR3A2 Antibody ([57/3]) - Azide and BSA Free [NBP2-61943] - Clone 57/3 used to detect expression of ER beta/NR3A2 in colorectal tissue by IHC-P. Examples of ER beta1 (a, d, e), ER beta/NR3A2 (b, f, g), ER beta 5 (c, h) and TFF1 (i) immunohistochemistry performed on normal colorectal epithelium (a-c) and colorectal carcinoma (d-i).](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([57-3])---Azide-and-BSA-Free-Immunohistochemistry-NBP2-61943-img0008.jpg)
![Western Blot: ER beta/NR3A2 Antibody ([PPG5/25]) - Azide and BSA Free [NBP2-61942] - Clone PPG5/25 used to detect ER beta/NR3A2 mRNA expression in colorectal carcinoma cells by Western Blot. (A) ER beta 1, 2 and ER beta/NR3A2 mRNA expression (assessed by RT-PCR) and (B) ER beta 1 and 2 protein expression (assessed by western blotting) by 10 colorectal carcinoma cell lines.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([PPG5-25])---Azide-and-BSA-Free-Western-Blot-NBP2-61942-img0009.jpg "Western Blot: ER beta/NR3A2 Antibody ([PPG5/25]) - Azide and BSA Free [NBP2-61942] - Clone PPG5/25 used to detect ER beta/NR3A2 mRNA expression in colorectal carcinoma cells by Western Blot. (A) ER beta 1, 2 and ER beta/NR3A2 mRNA expression (assessed by RT-PCR) and (B) ER beta 1 and 2 protein expression (assessed by western blotting) by 10 colorectal carcinoma cell lines.")
![Immunocytochemistry/Immunofluorescence: ER beta/NR3A2 Antibody ([PPG5/25]) - Azide and BSA Free [NBP2-61942] - Clone PPG5/25 used to detect ER beta/NR3A2 expression thymic tumors by Immunofluorescence. (A) Overexpression of cytoplasmic ER beta/NR3A2 was observed in thymic carcinomas and thymomas, compared with the normal thymic tissues. (B) ER beta/NR3A2 expression was observed in the T1682 and TC1889 cell lines through indirect immunofluorescence. (C) The results revealed that the mean level of ER beta/NR3A2 gene expression was lower in advanced clinical stages.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([PPG5-25])---Azide-and-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP2-61942-img0001.jpg)
![Immunohistochemistry: ER beta/NR3A2 Antibody ([PPG5/25]) - Azide and BSA Free [NBP2-61942] - Clone PPG5/25 used to detect expression of ER beta/NR3A2 in colorectal tissue by IHC-P. Examples of ER beta 1 (a, d, e), ER beta 2 (b, f, g), ER beta 2 (c, h) and TFF1 (i) immunohistochemistry performed on normal colorectal epithelium (a-c) and colorectal carcinoma (d-i).](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([PPG5-25])---Azide-and-BSA-Free-Immunohistochemistry-NBP2-61942-img0008.jpg)
![Immunohistochemistry: ER beta/NR3A2 Antibody ([PPG5/25]) - Azide and BSA Free [NBP2-61942] - Clone PPG5/25 used to detect expression of ER beta/NR3A2 in cancer tissue by IHC-P. Immunoexpression of ERs in endometrial cancers. Tissues were classified as well (A-D), moderately (E-H) or poorly (J-M) differentiated; main panels show closely adjacent sections from three cancer blocks to allow direct comparisons.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([PPG5-25])---Azide-and-BSA-Free-Immunohistochemistry-NBP2-61942-img0002.jpg)
![Immunohistochemistry: ER beta/NR3A2 Antibody ([PPG5/25]) - Azide and BSA Free [NBP2-61942] - Clone PPG5/25 used to detect expression of ER beta/NR3A2 in cancer tissue by IHC-P. A) Immunostaining for ER beta 1 was significantly higher in tumors from females compared to males (p<0.01); B) and C) Tumor levels of ER beta 2 and ER beta/NR3A2 did not significantly differ between females and males. All results are expressed as the mean +/- SEM (n=6 tumors/group). Representative stained section of tumors from females and males are shown (magnification 40x).](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([PPG5-25])---Azide-and-BSA-Free-Immunohistochemistry-NBP2-61942-img0005.jpg)
![Immunohistochemistry: ER beta/NR3A2 Antibody ([PPG5/25]) - Azide and BSA Free [NBP2-61942] - Clone PPG5/25 used to detect ER beta/NR3A2 expression in normal human liver by IHC-P. Staining pattern of the ER beta isoforms in human liver. In order to confirm the specificity of the ER beta antibodies,, sections of healthy human liver were immunostained, showing that ER beta 1 and ER beta 2 isoforms are not expressed, while specific nuclear ER beta 5 immunoreactivity is detected (magnification 20x and 40x). This pattern of ER beta isoforms' immunoreactivity is consistent with previous descriptions.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-([PPG5-25])---Azide-and-BSA-Free-Immunohistochemistry-NBP2-61942-img0007.jpg)
![Western Blot: ER beta/NR3A2 Antibody [NB300-747] - Analysis of ER beta was performed by loading the indicated amounts of recombinant full-length human ER alpha and ER beta proteins, and 10ul of PageRuler Prestained Protein Ladder per well onto a Novex® 4-20% Tris-Glycine polyacrylamide gel. Proteins were transferred to a PVDF membrane using the G2 Blotter, and blocked with 5% milk in TBST for at least 1 hour at room temp. ER beta was detected at ~54kD (left panel) using an ER beta polyclonal antibody at a dilution of 1:1000 in blocking buffer overnight at 4C on a rocking platform, followed by an HRP-conjugated goat anti-rabbit IgG secondary antibody at a dilution of 1:40,000. Chemiluminescent detection was performed using SuperSignal West Pico. The blot was then stripped with Restore Plus Western blot stripping buffer for at least 15 min at room temp, re-blocked with 5% milk in TBST for at least 1 hour at room temp, and re-probed with an ER alpha polyclonal antibody at a dilution of 1:2000 overnight at 4C, followed by an HRP-conjugated goat anti-rabbit IgG secondary antibody at a dilution of 1:40,000. Chemiluminescent detection was performed using SuperSignal West Pico. The presence of faint ER-beta bands on the blot probed.](http://images.novusbio.com/fullsize2/ER beta-NR3A2 Antibody-Western Blot-NB300-747-img0004.jpg "Western Blot: ER beta/NR3A2 Antibody [NB300-747] - Analysis of ER beta was performed by loading the indicated amounts of recombinant full-length human ER alpha and ER beta proteins, and 10ul of PageRuler Prestained Protein Ladder per well onto a Novex® 4-20% Tris-Glycine polyacrylamide gel. Proteins were transferred to a PVDF membrane using the G2 Blotter, and blocked with 5% milk in TBST for at least 1 hour at room temp. ER beta was detected at ~54kD (left panel) using an ER beta polyclonal antibody at a dilution of 1:1000 in blocking buffer overnight at 4C on a rocking platform, followed by an HRP-conjugated goat anti-rabbit IgG secondary antibody at a dilution of 1:40,000. Chemiluminescent detection was performed using SuperSignal West Pico. The blot was then stripped with Restore Plus Western blot stripping buffer for at least 15 min at room temp, re-blocked with 5% milk in TBST for at least 1 hour at room temp, and re-probed with an ER alpha polyclonal antibody at a dilution of 1:2000 overnight at 4C, followed by an HRP-conjugated goat anti-rabbit IgG secondary antibody at a dilution of 1:40,000. Chemiluminescent detection was performed using SuperSignal West Pico. The presence of faint ER-beta bands on the blot probed.")
![Immunohistochemistry-Frozen: ER beta/NR3A2 Antibody [NB300-747] - Staining of rat prostate.](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-Immunohistochemistry-Frozen-NB300-747-img0003.jpg)
![Immunohistochemistry-Paraffin: ER beta/NR3A2 Antibody (ERb455) [NBP2-29439] - Formalin-paraffin ovarian cancer stained with Estrogen receptor beta Ab (ERb455).](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-(ERb455)-Immunohistochemistry-Paraffin-NBP2-29439-img0004.jpg "Immunohistochemistry-Paraffin: ER beta/NR3A2 Antibody (ERb455) [NBP2-29439] - Formalin-paraffin ovarian cancer stained with Estrogen receptor beta Ab (ERb455).")
![Immunohistochemistry-Paraffin: ER beta/NR3A2 Antibody (ERb455) [NBP2-29439] - Formalin paraffin breast cancer stained with Estrogen receptor beta Ab (ERb455).](http://images.novusbio.com/fullsize2/ER-beta-NR3A2-Antibody-(ERb455)-Immunohistochemistry-Paraffin-NBP2-29439-img0003.jpg)
![Western Blot: Estrogen Receptor beta Antibody (6B12) [NB200-304] - Sample (30 ug of whole cell lysate) A: U87-MG B: SK-N-SH 7. 5% SDS PAGE; antibody diluted at 1:1000.](http://images.novusbio.com/fullsize2/Estrogen Receptor beta Antibody (6B12)-Western Blot-NB200-304-img0002.jpg "Western Blot: Estrogen Receptor beta Antibody (6B12) [NB200-304] - Sample (30 ug of whole cell lysate) A: U87-MG B: SK-N-SH 7. 5% SDS PAGE; antibody diluted at 1:1000.")